Abstract
A type II heparin-induced thrombocytopenia (HIT) was diagnosed in a 64-year-old woman at day 20 of intravenous unfractionated heparin (UFH) therapy, given after myocardial infarction treated by angioplasty and intracoronary stent. The infarction was complicated by a mitral insufficiency that led to a mitral valve replacement. Cardiopulmonary bypass was successfully performed with sodium danaparoid (Orgaran), as an alternative to UFH, without thrombotic or haemorrhagic complications and the follow-up was uneventful.
MeSH terms
-
Anticoagulants / therapeutic use*
-
Chondroitin Sulfates / therapeutic use*
-
Dermatan Sulfate / therapeutic use*
-
Drug Combinations
-
Extracorporeal Circulation*
-
Female
-
Heart Valve Prosthesis*
-
Heparin / adverse effects*
-
Heparitin Sulfate / therapeutic use*
-
Humans
-
Middle Aged
-
Mitral Valve Insufficiency / complications
-
Mitral Valve Insufficiency / surgery*
-
Thrombocytopenia / chemically induced*
-
Thrombocytopenia / complications
Substances
-
Anticoagulants
-
Drug Combinations
-
Dermatan Sulfate
-
Heparin
-
Chondroitin Sulfates
-
Heparitin Sulfate
-
danaparoid